(Q36969745)

17 August 2017

Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? (English)

1 reference

17 August 2017

multiple drug resistance

1 reference

1 reference

1 reference

Kwok-Chiu Chang

1

1 reference

17 August 2017

Wing-Wai Yew

2

1 reference

17 August 2017

Siu-Wai Cheung

3

1 reference

17 August 2017

Chi-Chiu Leung

4

1 reference

17 August 2017

Cheuk-Ming Tam

5

1 reference

17 August 2017

Chi-Hung Chau

6

1 reference

17 August 2017

Peter Kin-Ho Wen

7

1 reference

17 August 2017

Raphael Chiu-Yeung Chan

8

1 reference

17 August 2017

language of work or name

English

0 references

publication date

6 May 2013

1 reference

Antimicrobial Agents and Chemotherapy

17 August 2017

1 reference

17 August 2017

57

1 reference

17 August 2017

7

1 reference

17 August 2017

3445-3449

1 reference

Linezolid for treatment of chronic extensively drug-resistant tuberculosis

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

Peripheral neuropathy associated with prolonged use of linezolid

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

Hematologic effects of linezolid: summary of clinical experience

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

Intrapulmonary pharmacokinetics of linezolid

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

A high performance liquid chromatography (HPLC) assay for linezolid in continuous ambulatory peritoneal dialysis fluid (CAPDF).

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

Linezolid for treatment of vancomycin-resistant enterococcal peritonitis.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697330

Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients

4 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23650165

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.00388-13

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

23650165

1 reference